Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrexafungerp vs Fluconazole in Acute Vulvovaginal Candidiasis
NCT03253094Phase 2Completed
- Sponsor
- SCYNEXIS, Inc.
- Start
- Aug 2017
- Primary completion
- May 2018
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ibrexafungerp in vulvovaginal candidiasis (VVC) (6 arms), sponsored by SCYNEXIS, Inc. Primary endpoint: Clinical Cure (Complete Resolution of Signs and Symptoms). Started Aug 2017; status: completed.
02
Drugs
ibrexafungerp
03
Conditions
vulvovaginal candidiasis (VVC)
Beyond the preview
Go deeper on NCT03253094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03253094.